Novuson Surgical Inc.
OperatingHealthcare · Bothell, WA · Founded 2014
Electrosurgical devices that are safer and more effective than current devices
Financials
FY2019–FY2021 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Pre-money — the valuation set before each round’s money came inBlue bars are the pre-money valuation the company stated for a priced round.
Share price over rounds
Disclosed sales come from the issuer's own filings (prior-offering lines, audited-statement notes) and are amount ÷ securities sold. A down round is a firm point more than 25 % below the previous firm point of the same share class on a comparable basis; the comparison ignores unverified and year-only lines.
Fundraising history
Team
7 people
Experienced executive with a demonstrated history of working in the research industry and academia. Skilled in Bioreactor Development, Medical Devices, Biomedical Devices, Biomechanics, and Tissue Engineering. Strong entrepreneurship professional with a Doctor of Philosophy (Ph.D.) focused in Bioengineering from University of Washington.
Derek grew up in a small town in southwest Washington and is a graduate of the University of Washington School of Medicine, where he was the top graduate in his class. After a year of training in general surgery, Derek trained in Interventional Radiology at the University of Washington, where he was Chief Resident. He has a strong background in basic and clinical research and experience in medical device commercialization.
Mr. Daoura graduated from the University of Washington with both a Bachelor of Science in Electrical Engineering and a Master of Science in BioEngineering with focus on Control Theory and Molecular Biotechnology. He has over 20 years in the healthcare industry from Philips Healthcare to Fujifilm Medical Systems, UltraLinq Healthcare. His work in innovation crosses many multidisciplinary areas from technology development, to technology architecture, program management, product services, product management and marketing, and market commercialization.
Intellectually curious and passionate about people, process, and profit! I love to manage processes, create cross-functional teams, create high energy & high performing teams. I've succeeded in start-up environments, turn around scenarios and M&A integrations for both public and private companies by building plans, teams, campaigns, processes, from beginning to on-going concern. Pre-revenue to ~$50 Million in ARR. Experience in many technology markets: Healthcare, Automation, SAAS Platforms for Supply Chain and Healthcare, Enterprise infrastructure & applications, EAI, corporate portals, knowledge management, content management, search technology, XML infrastructure technology, security/user management, wireless/mobile apps, networking, groupware, personal productivity applications
Names and titles as disclosed on StartEngine, SEC Form C. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
Filed 1 of 5 annual reports (FY2021–FY2025)
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
- Form C-UJul 1, 20220001665160-22-001964EDGAR
- Form C-ARApr 29, 20220001665160-22-001215EDGAR
- Form C/AApr 28, 20220001665160-22-001099EDGAR
- Form C/AApr 13, 20220001665160-22-000647EDGAR
- Form CMar 25, 20220001665160-22-000534EDGAR
- Form DMar 31, 20200001591408-20-000006EDGAR
- Form DOct 19, 20150001655934-15-000001EDGAR
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.